Characteristics of HER2-Positive Breast Cancer according to HER2 2+/Low or 3+/High Classification by Immunohistochemistry Assay: Study of 205 Cases Treated in a Single Center

Changhee Lee; Inseok Park; Jungbin Kim; Hyunjin Cho; Keunho Yang; Yujin Lee; Kyeongmee Park; Jiyoung Kim; Youngjoo Shin; Geumhee Gwak

추천

검색

자료유형: 학술저널

저자정보: Changhee Lee (Department of Surgery Sanggye Paik Hospital Inje University College of Medicine) Inseok Park (Department of Surgery Sanggye Paik Hospital Inje) Jungbin Kim (Department of Surgery Sanggye Paik Hospital Inje) Hyunjin Cho (Department of Surgery Sanggye Paik Hospital Inje) Keunho Yang (Department of Surgery Sanggye Paik Hospital Inje University College of Medicine Seoul Korea) Yujin Lee (Department of Surgery Sanggye Paik Hospital Inje University College of Medicine Seoul Korea) Kyeongmee Park (Department of Pathology Sanggye Paik Hospital Inje University College of Medicine Seoul Korea) Jiyoung Kim (Department of Radiology Sanggye Paik Hospital Inje University College of Medicine Seoul Korea) Youngjoo Shin (Department of Radiation Oncology Sanggye Paik Hos) Geumhee Gwak (Department of Surgery Sanggye Paik Hospital Inje University College of Medicine Seoul Korea)

저널정보: 한국유방암학회 Journal of Breast Disease Journal of Breast Disease 제9권 제1호

발행연도: 2021.1

수록면: 1 - 9 (9page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose: To investigate the characteristics of HER2-positive breast cancer according to HER2 low (2+) or high (3+) classification using immunohistochemistry (IHC). Methods: Data were collected from 205 HER2-positive breast cancer patients in the final assay, regardless of IHC or in situ hybridization (ISH). We thus classified patients into two groups: HER2 2+/low and HER2 3+/high based on the IHC assay. We subsequently compared the clinical and pathological characteristics between groups. Results: The median patient age was 49 years in the HER2 2+/low group and 53 years in the HER2 3+/high group. We observed a significantly lower Allred score for estrogen receptor (ER) and progesterone receptor (PR) (0-6) (p<0.001), less lymphatic invasion (LI), (p=0.010), neural invasion (p=0.041), higher Ki-67 (p=0.001), and lower Bcl-2 (p<0.001) in the HER2 3+/high group than in the HER2 2+/low group. Lymph node recurrence was more frequently observed in the HER2 2+/low group than in HER2 3+/high group (p=0.005). Disease-free survival (DFS) was better in the HER2 3+/high group than in the HER2 2+/low group (p=0.028), but there were no significant differences in overall survival between the groups (p=0.233). Conclusion: The HER2 3+/high group was associated with lower ER and PR expression, less LI, higher Ki-67, and lower Bcl-2 than that in HER2 2+/low group in HER2-positive breast cancer. Furthermore, compared to the HER2 2+/low group, the HER2 3+/high group had an improved DFS.

#Breast neoplasms #Human epidermal growth factor receptor 2 #Immunohistochemistry #Prognosis

참고문헌 (28)

참고문헌 신청

Hudis CA / 2007 / Trastuzumab—mechanism of action and use in clinical practice / N Engl J Med 357:30~51

Meric-Bernstam F / 2006 / Advances in targeting human epi-dermal growth factor receptor-2 signaling for cancer therapy / Clin Cancer Res 12:6326~6330

Slamon DJ / 1987 / Human breast cancer : correlation of relapse and survival with amplification of the HER-2/neu onco-gene / Science 235:177~182

Slamon DJ / 1989 / Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer / Science 244:707~712

Gabos Z / 2006 / Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diag-nosed breast cancer / J Clin Oncol 24:5658~5663

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!